 Home > Biochemistry News > Biotechnology News > Innovative anti-cancer therapy using red blood cells to extensively stimulate the immune system enters the clinic

Innovative anti-cancer therapy using red blood cells to extensively stimulate the immune system enters the clinic

 Last Update: 2022-01-24
 Source: Internet
 Author: User

Tags

dnase treatment

lice treatment walgreens

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On January 13, 2022, Rubius Therapeutics announced that it has completed the first patient dosing in a Phase 1/2 clinical trial of its red blood cell therapy RTX-224, designed to broadly stimulate the immune system, for the treatment of certain relapsed/refractory Patients with sexually advanced or locally advanced solid tumors, including non-small cell lung cancer, cutaneous melanoma, head and neck squamous cell carcinoma, urothelial (bladder) cancer, and triple-negative breast cancer

Rubius aims to bioengineer red blood cells to create an entirely new class of cellular drugs for the treatment of cancer and autoimmune diseases

Image source: Rubius official website

This open-label, multicenter, multidose, dose-escalation and expansion Phase 1/2 clinical trial is designed to determine the safety, resistance to RTX-224 in certain adult patients with relapsed/refractory or locally advanced solid tumors Tolerance, pharmacokinetics, maximum tolerated dose, and recommended Phase 2 dose and dosing schedule

References:

[1] Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors.

(Original abridged)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Express uses red blood cells to extensively stimulate the immune system, and innovative anti-cancer therapy enters the clinic

01-24

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Innovative anti-cancer therapy using red blood cells to extensively stimulate the immune system enters the clinic

Related Articles

Express uses red blood cells to extensively stimulate the immune system, and innovative anti-cancer therapy enters the clinic